{
    "clinical_study": {
        "@rank": "72038", 
        "acronym": "TENOR", 
        "arm_group": {
            "arm_group_label": "TCZ", 
            "arm_group_type": "Experimental", 
            "description": "Tocilizumab at week 0, week 4 and week 8 8mg/kg at each perfusion"
        }, 
        "brief_summary": {
            "textblock": "Phase 1:\n\n      Patients are treated with infusions of Tocilizumab (TCZ) for 3 months. Clinical evaluation\n      is performed using PMR-AS.\n\n      The PMR-AS is computed by summing the 5 variables after multiplying by 0.1 for weighting\n      purposes: PMR-AS (activity scale = AS) = C reactive protein (CRP) (mg/dl) + patient scale\n      (VASp) (0-10 scale) + physician scale (VASph) (0-10 scale) + morning stiffness(MST)\n      [min]\u00d70.1) + elevation of upper limbs (EUL) (0-3 scale).\n\n      At the end of the phase 1,the patients stop TCZ and entered in phase 2 at week 12.\n\n      Phase 2:\n\n      All the patients are included in the phase 2 and treated with glucocorticoid (GC)for 3\n      months. Two arms are possible according to the PMR-AS. Either the classical GC treatment\n      (0.3mg/kg), either a low dose group of GC(0.15mg/kg) ."
        }, 
        "brief_title": "Tocilizumab Effect iN pOlymyalgia Rheumatica", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Polymyalgia Rheumatica", 
        "condition_browse": {
            "mesh_term": [
                "Polymyalgia Rheumatica", 
                "Giant Cell Arteritis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 50 years and 75 years included\n\n          -  PMR-AS > 10\n\n          -  PMR according to the Chuang criteria\n\n          -  Evolving since less than 12 months\n\n          -  Without Horton disease\n\n          -  Able to understand and accept the study\n\n          -  Agree to sign the inform consent form\n\n          -  Without GC, or at least during 1 month and stop since 7 days before the inclusion.\n\n          -  Stable dose of Nonsteroidal anti-inflammatory since 4 weeks before the inclusion.\n\n          -  Birth controlled during all the study and 6 months after\n\n        Exclusion Criteria:\n\n          -  Disagree to participated\n\n          -  Unable to understand the study\n\n          -  Participation to an other study in the 3 months before the inclusion\n\n          -  Treated by GC at 0.3mg/kg/d in the past 7 days\n\n          -  Less than 50 years old or more than 75 years old\n\n          -  Uncontrolled dyslipidemia,  high blood pressure or cardiovascular disease\n\n          -  Histories of important allergy\n\n          -  Historically positive test or test positive at screening for HIV-1 antibody,\n             hepatitis B surface antigen, or hepatitis C antibody.\n\n          -  Abnormal screening blood test : leukocyte count less than 3.5 \u00d7 109 cells/L,\n             neutrophil count less than 2 \u00d7 109 cells/L, hemoglobin level less than 85 g/L,\n             platelet count less than 100 \u00d7 109 cells/L, or hepatic aminotransferase or alkaline\n             phosphatase levels greater than 3 times the upper limit of normal\n\n          -  Other inflammatory rheumatic disease or connective disease\n\n          -  Clinical evidence of significant unstable or uncontrolled acute or chronic diseases\n             not due to PMR (eg. Cardiovascular, pulmonary, hematologic, gastrointestinal,\n             hepatic, renal, neurological, malignancy or infectious diseases)\n\n          -  Current drug or alcohol abuse\n\n          -  Patients  treated with an immunosuppressive agents in the past 4 weeks\n\n          -  Live/attenuated vaccine in the past 4 weeks\n\n          -  Clinical symptoms of giant cell arteritis\n\n          -  History of infection or infestation in the past 3 months\n\n          -  Active tuberculosis\n\n          -  Planned surgical procedure\n\n          -  History of malignant neoplasm within the last 5 years, except for adequately treated\n             cancer of the skin (basal or squamous cell)\n\n          -  History or current tumoral hematological disease\n\n          -  Severe allergic or anaphylactic reactions about one of the TCZ component\n\n          -  Pregnant women during the study and six month after the end of the study\n\n          -  Breast feeding mother\n\n          -  Dysthyroidia\n\n          -  Unstable treatment by statin in the past 3 months\n\n          -  Parkinson disease\n\n          -  Fibromyalgia\n\n          -  Peripheric arthritis\n\n          -  Articular chondrocalcinosis or hydorxyapatites rhumatisms"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01713842", 
            "org_study_id": "RB 11-075 TENOR"
        }, 
        "intervention": {
            "arm_group_label": "TCZ", 
            "description": "Tocilizumab at week 0, 4 and 8.", 
            "intervention_name": "TCZ", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Tocilizumab", 
            "Polymyalgia Rheumatica", 
            "Glucocorticotherapy", 
            "PMR-AS"
        ], 
        "lastchanged_date": "June 28, 2013", 
        "location": [
            {
                "contact": {
                    "email": "valerie.devauchelle-pensec@chu-brest.fr", 
                    "last_name": "Val\u00e9rie DEVAUCHELLE, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "France", 
                        "zip": "29609"
                    }, 
                    "name": "Brest University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Val\u00e9rie DEVAUCHELLE, Pr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Alain SARAUX, Pr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Divi CORNEC, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Thierry MARHADOUR, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jean-Marie BERTHELOT, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44000"
                    }, 
                    "name": "Nantes University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jean-Marie BERTHELOT, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orl\u00e9ans", 
                        "country": "France", 
                        "zip": "45000"
                    }, 
                    "name": "CHR d'Orl\u00e9ans"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Open 24 Weeks Study to Evaluate Effect and Safety of Tocilizumab as the First Line Therapy in Subjects With Polymyalgia Rheumatica (PMR)", 
        "overall_contact": {
            "email": "valerie.devauchelle-pensec@chu-brest.fr", 
            "last_name": "Val\u00e9rie DEVAUCHELLE, Pr"
        }, 
        "overall_official": {
            "affiliation": "CHRU de Brest", 
            "last_name": "Val\u00e9rie DEVAUCHELLE, Pr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PMR-AS at week 12", 
            "measure": "Efficacy at W12", 
            "safety_issue": "No", 
            "time_frame": "12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01713842"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To maintain low disease activity (PMR-AS) in the low corticosteroid dose group from W12 to W24\nOn the inflammatory changes (synovitis, myositis, tenosynovitis aund bursitis) between baseline, W2 and 12 visualize by ultrasonography, MRI and Tep-Scan.\nOn sparing corticosteroid, with the comparison of the cumulative corticosteroid dosage beetwen the two groups of patients in the phase 2, W12 to 24.\nOn the circulating serum cytokines and immunoregulators (IL-6, IL-1, BLyS/BAFF, IL-6 receptor, gp130) and B cells receptors and on the phenotype of circulating T- and B-cells  between baseline and W4 and 12 On inflammatory parameters (CRP and ESR) between baseline and W 2,4,8,12,16,20 and 24\nOn the quality of life of patients between baseline and W 4,12,16, 20 and 24\nTo evaluate the side-effects in relation to the use of Tocilizumab treatment. [ Time Frame: After first, second and third treatment and during follow up ]", 
            "measure": "Safety and efficacy during the study", 
            "safety_issue": "Yes", 
            "time_frame": "Week 2,4,8,12,16,20 and 24"
        }, 
        "source": "University Hospital, Brest", 
        "sponsors": {
            "collaborator": {
                "agency": "Chugai Laboratory", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University Hospital, Brest", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}